3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
233
Lung Neoplasms
96
Adenocarcinoma of Lung
39
Colorectal Neoplasms
21
Adenocarcinoma, Bronchiolo-Alveolar
19
Neoplasms
18
Small Cell Lung Carcinoma
13
Non-Squamous Non-Small Cell Lung Cancer
13
Brain Neoplasms
13
Neoplasm Metastasis
10
Ovarian Neoplasms
9
Pleural Effusion, Malignant
8
Breast Neoplasms
8
Stomach Neoplasms
7
Pancreatic Neoplasms
7
Meningeal Carcinomatosis
7
Mesothelioma
6
Melanoma
6
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Rectal Neoplasms
4
Non-squamous Non-small Cell Lung Cancer
4
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Non-small Cell Lung Cancer Metastatic
3
Mesothelioma, Malignant
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Interventions
toripalimab
1
pelcitoclax
1
osimertinib
1
Pemetrexed
1
Paclitaxel
1
Injections
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
EGFR Positive Non-small Cell Lung Cancer
×
Bevacizumab
×
Thoracic
×
Clear all
NCT03126799
2022-04-06
AvaTa
National Cancer Center, Korea
Phase 2
Unknown
128 enrolled